Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

sections

Prescribing

Public Health England reminds prescribers of effectiveness of antivirals for flu

Public Health England (PHE) has instructed doctors to prescribe antivirals for patients with influenza who are severely unwell or members of at-risk groups and not to be swayed by data showing that these drugs may not be effective.

In a letter issued ahead of the 2014–2015 flu season, PHE cites evidence that antivirals can substantially reduce the risk of death in patients admitted to hospital with flu.

In April 2014, a Cochrane review[1] concluded that the antivirals zanamivir and oseltamivir — both neuraminidase inhibitors — were not very effective at treating flu. Public health officials fear that this conclusion might deter doctors from prescribing the drugs to patients who need them and so they highlight that the Cochrane review did not consider the “substantial volume” of observational data and that the patients included in the trials were otherwise healthy.

One of the observational meta-analyses[2] cited by PHE, which included 29,234 patients, concluded that in those who were hospitalised with flu, there was a 25% reduction in risk of death when patients were treated with neuraminidase inhibitors. This increased to a 50% reduction in risk of death when treatment was initiated in the first two days of illness.

“It is essential that physicians treating severely unwell patients in any setting are not deterred from prescribing what may be lifesaving drugs as a result of confusion over efficacy in this situation; this is especially true for patients hospitalised with proven or suspected flu,” says Paul Cosford, director for health protection and medical director at PHE.

 

 

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2014.20067088

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.